Document is current
Any future updates will be listed below
-
Authors
Saunders, Elizabeth C. https://orcid.org/0000-0002-2728-0001
Satcher, Milan F.
Monico, Laura B.
McDonald, Ryan D.
Springer, Sandra A.
Farabee, David
Gryczynski, Jan
Nyaku, Amesika
Reeves, Donald
Kunkel, Lynn E.
Schultheis, Alysse M.
Schwartz, Robert P.
Lee, Joshua D.
Marsch, Lisa A.
Waddell, Elizabeth Needham
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (U01-DA047982)
- License Information
-
More Information
Article History
Received: 12 August 2022
Accepted: 6 December 2022
First Online: 19 December 2022
Declarations
:
: This study was approved by the New York University School of Medicine Institutional Review Board (study reference number: S19–01450) and consent was obtained through the web-based survey platform.
: Not applicable.
: Drs. Lee, Springer, Farabee, and Waddell have received in-kind study drug from Indivior and Alkermes for other federally funded trials. Dr. Springer has provided scientific consultation for Alkermes. Dr. Schwartz has provided consultation for Verily Life Sciences. Dr. Marsch is affiliated with Pear Therapeutics, Inc. and Square2 Systems, Inc. Dr. Gryczynski is part owner of COG Analytics. Drs. Gryczynski, Lee, and Monico have received research funding from Indivior for conduct of a health survey study.
